Clinical Trials Logo

Clinical Trial Summary

This is a randomized, rt-PA controlled, open-label phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus rt-PA thrombolysis for patients with acute ischaemic stroke in 4.5 hours after stroke onset.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03541668
Study type Interventional
Source Tasly Biopharmaceuticals Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date May 18, 2018
Completion date May 24, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03463551 - Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic Phase 2
Completed NCT02164357 - Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset N/A
Recruiting NCT01207336 - Combined tDCS+PNS After Acute Stroke Phase 2/Phase 3
Completed NCT03328403 - Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion N/A
Completed NCT03971526 - Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke
Recruiting NCT03639922 - Imatinib in Acute Ischaemic Stroke Phase 3
Completed NCT03865225 - Effects of Heart Rate Variability Biofeedback in Patients With Acute Ischemic Stroke N/A
Completed NCT03354429 - THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death Phase 3
Completed NCT01994720 - [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Phase 3
Terminated NCT01745692 - Pragmatic Ischaemic Stroke Thrombectomy Evaluation N/A
Completed NCT03578822 - Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial Phase 3